Lung cancer in HIV-infected patients

AIDS Reviews

Volumn 18, Issue 3, 2016, Pages 138-144

  Mena, Álvaro ^a   Meijide, Héctor ^a,b   Marcos, Pedro J ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

Author keywords

Cancer screening; HIV; Lung cancer; PLWH; Smoking

Indexed keywords

CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; ETHNIC DIFFERENCE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG INFECTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OXIDATIVE STRESS; PNEUMONIA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SMOKING CESSATION; T LYMPHOCYTE; VIRUS LOAD; ADVERSE EFFECTS; COMPLICATION; HIV INFECTIONS; LUNG NEOPLASMS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS;

EID: 84990833528     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Causespecific life expectancies after 35 years of age for HIV-infected and HIV-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013; 177: 116-25.
2. Shiels M, Pfeiffer R, Gail M, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103: 753-62.
3. Brenner A, Wang Z, Kleinerman R, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol. 2001; 30: 118-24.
4. Helleberg M, Gerstoft J, Afzal S, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014; 28: 1499-508.
5. Patel P, Hanson D, Sullivan P, et al. Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigator. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148: 728-36.
6. Silverberg M, Lau B, Achenbach C, et al. Cumulative Incidence of Cancer Among Persons With HIV in North America. Ann Intern Med. 2015; 163: 507-18.
7. Deeken J, Tjen-A-Looi A, Rudek M, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012; 55: 1228-35.
8. Meijide H, Mena A, Pernas B, et al. Malignancies in HIV-infected patients: descriptive study of 129 cases between 1993 and 2010. Rev Chilena Infectol. 2013; 30: 156-61.
9. Robbins H, Pfeifer R, Shiells M, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015; 6; 107: 4.
10. Clifford G, Lise M, Franceschi S, et al. Lung cancer in the Swiss Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer. 2012; 106: 447-52.
11. Chaturvedi A, Pfeiffer R, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS. 2007; 21: 207-13.
12. Calvo M, Laguno M, Martínez M, Martínez E. Effects of tobacco smoking on HIV-infected individuals. AIDS Rev. 2015; 17: 47-55.
13. Brock M, Hooker C, Engels E, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43: 47-55.
14. Engels E, Pfeiffer R, Goedert J, et al. Study HAC. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20: 1645-54.
15. Hakimian R, Fang H, Thomas L, Edelman M. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol. 2007; 2: 268-72.
16. Lavole A, Chouaid C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV-infected patients with non-small-cell lung cancer. Lung Cancer. 2009; 65: 345-50.
17. D’Jaen G, Pantanowitz L, Bower M, et al. HIV-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010; 11: 396-404.
18. Pakkala S, Chen Z, Rimland D, et al. HIV-associated lung cancer in the era of highly active antiretroviral therapy. Cancer. 2012; 118: 164-72.
19. Okuma Y, Tanuma J, Kamiryo H, et al. A multiinstitutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living HIV infection. J Canc Res Clin Oncol. 2015; 141: 1669-78.
20. Meijide H, Mena A, Marcos P, et al. Lung cancer in patients living with HIV infection. AIDS. 2015; 29: 2363-4.
21. Coghill A, Shiells M, Suneja G, Engles E. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2014; 33: 2376-83.
22. Winstone T, Paul Man S, Hull M, Montaner J, Sin D. Epidemic of lung cancer in patients with HIV infection. Chest. 2013; 143; 305-14.
23. Hessol N, Martinez-Maz O, Levine A, et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. 2015; 29: 1183-93.
24. Alavanja M, Brownson R, Boice J, Hock E. Pre-existing lung disease and lung cancer among non-smoking women. Am J Epidemiol. 1992; 136: 623-32.
25. Dheda K, Booth H, Huggett J, Johnson M, Zumla A, Rook G. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005; 192: 1201-9.
26. Schabath M, Delclos G, Martynowicz M, et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005; 161: 412-22.
27. Wu A, Fontham E, Reynolds P et al. Previous lung disease and risk of lung cancer among lifetime non-smoking women in the United States. Am J Epidemiol. 1995; 141: 1023-32.
28. Clarke J, Gates A, Coker R, et al. HIV-1 proviral DNA copy number in peripheral blood leucocytes and bronchoalveolar lavage cells of AIDS patients. Clin Exp Immunol. 1994; 96: 182-6.
29. Horiike M, Iwami S, Kodama M, et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology. 2012; 423: 107-18.
30. Gordon S, Janoff E, Sloper D, et al. HIV-1 infection is associated with altered innate pulmonary immunity. J Infect Dis. 2005; 192: 1412-6.
31. Jambo K, Banda D, Kankwatira A, et al. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. Mucosal Immunol. 2014; 7: 1116-26.
32. Segal L, Methé B, Nolan A, et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc Am Thorac Soc. 2011; 8: 282-7.
33. Tange S, Oktyabri D, Terashima M, et al. JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines. PloS One. 2014; 9: e115684.
34. Chen H, Wang JW, Liu L, et al. Expression and significance of transforming growth factor-beta receptor type II and DPC4/Smad4 in non-small cell lung cancer. Exp Ther Med. 2015; 9: 227-31.
35. Malherbe G, Steel HC, Cassol S, et al. Circulating biomarkers of immune activation distinguish viral suppression from non-suppression in HAARTtreated patients with advanced HIV-1 subtype C infection. Mediators Inflamm. 2014; 2014: 198413.
36. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi’s sarcoma with and without visceral involvement. J Clin Oncol. 2006; 24: 3408-14.
37. Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDSrelated lymphoma. AIDS. 2003; 17: 1521-9.
38. Chao C, Leyden W, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012; 26: 2223-31.
39. Twigg H, Cnox K. Impact of antiretroviral therapy on lung immunology and inflammation. Clin Chest Med. 2013; 34: 155-64.
40. Cribbs S, Guidot D, Martin G, et al. Antiretroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals. PLoS One. 2014; 9: e88630.
41. Anttila S, Raunio H, Hakkola J. Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and crosstalk in lung carcinogenesis. Am J Respir Cell Mol Biol. 2011; 44: 583-90.
42. Bruyand M, Le Marec F, Lavole A, et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS. 2015; 29: 1105-9.
43. Bañón S, Machuca I, Araujo S, et al. Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. J Int AIDS Soc. 2014; 17: e19590.
44. Torres H, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretroviral in HIV-infected patients with cancer. Clin Microbiol Infect. 2014; 20: 672-9.
45. Aberle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
46. American Lung Association. Providing guidance on lung cancer screening to patients and physicians. 2012 Available at: http://www.lung.org/lungdisease/lung-cancer/lung-cancer-screening- guidelines/lung-cancerscreening. pdf. [Accessed 2015 Oct 17].
47. Detterbeck F, Mazzone P, Naidich D, Bach P. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e78-92S.
48. Jaklitsch M, Jacobson F, Austin J, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012; 144: 33-8.
49. Wender R, Fontham E, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63: 107-17.
50. Bach P, Gould M. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med. 2012; 157: 571-3.
51. de Torres J, Bastarrika G, Wisnivesky J, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007; 132: 1932-8.
52. Wilson D, Weissfeld J, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008; 178: 738-44.
53. Hulbert A, Hooker C, Keruly J, et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol. 2014; 9: 752-9.
54. Pathak V, Rendon I, Hasalla I, Tsegaye A. Evaluation of solitary pulmonary nodule in HIV- infected patients. Respir Care. 2012; 57: 1115-20.
55. Gritz E, Danysh H, Fletcher F, et al. Long-term outcomes of a cell phonedelivered intervention for smokers living with HIV/AIDS. Clin Infect Dis. 2013; 57: 608-15.
56. Humfleet G, Hall S, Delucchi K, et al. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013; 15: 1436-45.
57. Moscou-Jackson G, Commodore-Mensah Y, Farley J, DiGiacomo M. Smoking cessation interventions in people living with HIV infection: A systematic review. J Assoc Nurses AIDS Care. 2014; 25: 32-45.
58. Ferketich A, Diaz P, Browning K, et al. Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res. 2013; 15: 247-54.
59. Cui Q, Robinson L, Elston D, et al. Safety and tolerability of varenicline tartrate (Champix®/Chantix®) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS. 2012; 26: 12-9.
60. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006; 24: 1383-8.